Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. Chief Operating Officer Margaret Horn reported a sale of company stock in an insider filing. On 12/16/2025, she disposed of 4,847 shares of common stock at a price of $76.8173 per share. The filing states this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to cover tax withholding obligations triggered by the vesting of restricted stock units.
After this transaction, Horn beneficially owned 141,053 shares of Revolution Medicines common stock, which includes 61,226 restricted stock units. The form indicates the holdings are directly owned.
Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale. CFO Jack Anders disclosed the sale of 3,104 shares of common stock on 12/16/2025 at a price of $77.0904 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy his tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.
Following this transaction, Anders beneficially owns 108,065 shares of Revolution Medicines common stock. This figure includes 175 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025 and 42,338 restricted stock units, which represent a right to receive shares in the future subject to vesting conditions.
Revolution Medicines, Inc. (RVMD) reported an insider stock transaction by its Chief Financial Officer, Jack Anders. On 11/25/2025, Anders exercised a stock option for 5,418 shares of common stock at an exercise price of $17 per share, then sold 5,418 shares of common stock at a price of $74 per share. The filing notes that the transaction was made under a Rule 10b5-1 trading plan adopted on December 16, 2024, which is designed to pre-arrange trades. After these transactions, Anders directly holds 110,994 shares of common stock, which includes 48,275 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported insider activity by President, Chief Executive Officer and Director Mark A. Goldsmith. On 11/25/2025, he exercised a stock option to buy 60,000 shares of common stock at an exercise price of $4.09 per share, then sold 60,000 shares of common stock in a transaction under code M/S.
He also reported open market sales of 3,000 shares of common stock at $75 per share from each of two trusts. A weighted average sale price of $75.0827 was reported for one of the sales executed in multiple trades. After these transactions, he directly beneficially owned 247,863 shares of common stock (including 193,475 restricted stock units), and held additional indirect positions of 67,424 shares in each of two revocable trusts and 570,050 shares in a separate revocable living trust. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.
Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported an option exercise and stock sale. On 11/18/2025, he exercised a stock option for 20,000 shares of common stock at an exercise price of $4.09 per share, then sold 20,000 shares of common stock in open market transactions at a weighted average price of $70.3793 per share.
After these transactions, he directly beneficially owned 247,863 shares of common stock, which includes 193,475 restricted stock unitsRule 10b5-1 trading plan adopted on December 19, 2024, indicating the trades were pre-arranged under that plan.
Revolution Medicines, Inc. (RVMD) reported an insider equity transaction by its General Counsel, who is an officer of the company. On 11/18/2025, the officer exercised a stock option for 13,388 shares of common stock at an exercise price of $42.45 per share, then sold 13,388 shares of common stock on the same date at a weighted average price of $70.138 per share. After these transactions, the officer beneficially owned 50,425 shares of common stock, which includes 43,910 restricted stock units. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025.
Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.
After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.
Revolution Medicines (RVMD) — Form 4 insider activity: President and CEO Mark A. Goldsmith reported option exercises and share sales on 11/07/2025 pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. He exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, then sold 30,000 shares at a weighted average price of $60.3102 (trades ranged from $60.00 to $60.88).
On 11/12/2025, he recorded transfers of 50,000 shares to the Jonathan Goldsmith Revocable Trust and 50,000 shares to the Rebecca Goldsmith Revocable Trust, and reported indirect holdings in multiple family trusts. Following the transactions, direct beneficial ownership amounts were updated across entries, and his beneficial holdings include 193,475 restricted stock units.
Revolution Medicines (RVMD) reported a larger quarterly loss as it accelerates development of its RAS(ON) therapies. For the quarter ended September 30, 2025, net loss was $305.2 million or $1.61 per share, compared with $156.3 million a year ago. Operating expenses rose to $315.3 million, driven by research and development of $262.5 million and general and administrative of $52.8 million.
Liquidity remains strong with $217.4 million in cash and equivalents and $1.714 billion in marketable securities (total $1.93 billion) as of September 30, 2025, and management believes existing resources will fund operations for at least 12 months. RVMD entered a $250.0 million revenue participation agreement with Royalty Pharma, recorded as a liability of $256.5 million, with tiered royalty rates of 2.55% up to $2.0 billion in annual sales, 1.50% between $2.0–$4.0 billion, and 0.60% between $4.0–$8.0 billion. The company also established a senior secured term loan facility of up to $750.0 million, contingent on future regulatory and commercial milestones, with no amounts drawn. Shares outstanding were 189,710,951 as of September 30, 2025.
Revolution Medicines (RVMD) filed an 8-K announcing financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The information in the report and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. Listed securities include common stock (RVMD) and warrants expiring 2026 (RVMDW) on Nasdaq.